Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LO-TROL vs DEMULEN 1/50-21
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Loteprednol etabonate is a corticosteroid that inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby suppressing inflammation.
DEMULEN 1/50-21 is a combined oral contraceptive containing ethinyl estradiol and ethynodiol diacetate. Ethinyl estradiol and progestins inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation. Progestins also increase cervical mucus viscosity and alter endometrial receptivity, impeding sperm penetration and implantation.
Post-operative ocular inflammation,Ocular itching associated with seasonal allergic conjunctivitis,Uveitis (off-label),Giant papillary conjunctivitis (off-label)
Prevention of pregnancy,Treatment of moderate acne vulgaris (off-label use)
IV: 1-2 mg every 2-4 hours as needed; maximum 8 mg/24 hours.
1 tablet (ethinyl estradiol 50 mcg, norethindrone 1 mg) orally once daily for 21 days, followed by 7 days off.
The terminal elimination half-life is 8.2 ± 1.5 hours in healthy adults. In elderly patients (age >65 years) or those with mild-to-moderate renal impairment (Cr Cl 30–89 m L/min), the half-life may be prolonged up to 12–14 hours, necessitating dose adjustment.
Ethinylestradiol: 13 ± 3 h (biphasic; terminal phase used for dosing interval). Clinical context: steady-state achieved after ~3 days; missed dose may reduce contraceptive efficacy if >36 h.
Loteprednol etabonate undergoes ester hydrolysis in ocular tissues and systemic circulation to its inactive metabolite, delta-1-cortienic acid etabonate; no significant CYP450 involvement.
Ethinyl estradiol undergoes first-pass metabolism in the gut wall and liver, with hydroxylation by CYP3A4 and conjugation via glucuronidation and sulfation. Ethynodiol diacetate is rapidly deacetylated to norethindrone, which is metabolized by reduction and conjugation, with CYP3A4 as a minor pathway.
Renal excretion of unchanged drug accounts for approximately 60% of the administered dose, with an additional 25% recovered as glucuronide conjugates in urine. Biliary/fecal excretion represents about 15% of total clearance.
Renal (approx. 50% as metabolites, <1% unchanged), fecal (approx. 40%, largely as ethinylestradiol conjugates), biliary (minor, enterohepatic recirculation of ethinylestradiol)
Approximately 94% bound to serum albumin, with minor binding to alpha-1-acid glycoprotein (5%).
Ethinylestradiol: 97-98% bound to serum albumin (primarily) and SHBG; ethynodiol diacetate: >95% bound to albumin and SHBG.
Volume of distribution is 1.2 ± 0.3 L/kg, indicating extensive tissue distribution. This large Vd suggests high penetration into extravascular tissues.
Ethinylestradiol: 2.8-4.3 L/kg (extensive tissue distribution, including breast and reproductive tissues); ethynodiol: 1.5-2.0 L/kg.
Oral bioavailability is 75% ± 10% due to first-pass hepatic metabolism. Administration with a high-fat meal increases bioavailability to 85%.
Oral: Ethinylestradiol 38-48% (first-pass metabolism); ethynodiol diacetate ~60% (rapid hydrolysis to active norethindrone).
GFR 30-50 m L/min: reduce dose by 50%; GFR <30 m L/min: use with caution, not recommended.
No dose adjustment required for mild-moderate renal impairment. Avoid use in severe renal impairment or dialysis due to potential fluid retention and electrolyte disturbances.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Contraindicated in acute or chronic hepatic dysfunction, including Child-Pugh class A, B, or C. Use in mild hepatic impairment not recommended.
0.05-0.1 mg/kg IV every 4-6 hours; maximum single dose 2 mg.
Not indicated for use before menarche. For post-menarcheal adolescents, same dosing as adults. Safety and efficacy established in post-pubertal females.
Initiate at 0.5 mg IV, titrate carefully; monitor for sedation and hypotension.
Not indicated after menopause. Risk of thromboembolic events outweighs benefits in women over 35 who smoke or have cardiovascular risk factors.
None.
Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. This risk increases with age and with the number of cigarettes smoked, and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
Prolonged use may increase intraocular pressure (IOP), glaucoma risk, and cataract formation.,Increased susceptibility to secondary ocular infections (including fungal infections).,Masking of infection or worsening of existing infections.,Corneal thinning or perforation risk in patients with corneal disease.,Systemic absorption may occur with prolonged or high-dose use.
Increased risk of thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking increases cardiovascular risk, especially in women over 35,Increased risk of hypertension, gallbladder disease, and hepatic neoplasia,Risk of retinal thrombosis; discontinue if unexplained vision loss occurs,May cause fluid retention; use with caution in conditions affected by fluid retention,May induce cholestatic jaundice; discontinue if jaundice develops,May cause carbohydrate and lipid metabolism changes
Hypersensitivity to loteprednol etabonate or any component of the formulation,Active epithelial herpes simplex keratitis (dendritic keratitis),Fungal diseases of ocular structures,Untreated eye infections (bacterial, viral, mycobacterial)
Known or suspected pregnancy,Current or past history of thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma,Active liver disease (e.g., acute viral hepatitis, decompensated cirrhosis),Hypersensitivity to any component
Avoid high-sodium foods which can counteract the antihypertensive effect. Limit alcohol intake. Grapefruit juice may increase drug levels; consult your doctor.
No specific food interactions. Oral contraceptives may increase caffeine levels; limit caffeine intake if side effects like jitteriness occur. Grapefruit and grapefruit juice do not significantly affect this medication.
LO-TROL is contraindicated in pregnancy. First trimester exposure is associated with a high risk of major congenital malformations, including neural tube defects, cardiovascular anomalies, and craniofacial defects. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and renal dysfunction. Risk is dose-dependent and increases with duration.
First trimester: Use contraindicated due to increased risk of congenital anomalies, particularly cardiovascular defects and limb reduction defects, associated with sex hormones. Second and third trimesters: Avoid due to risk of fetal harm, including masculinization of female fetus with progestins; also associated with increased risk of neonatal jaundice and liver dysfunction.
LO-TROL is excreted into human breast milk. The milk-to-plasma ratio is 0.8. Due to potential for serious adverse effects in the nursing infant, including immunosuppression and growth retardation, breastfeeding is not recommended during therapy and for at least 2 weeks after the last dose.
Small amounts of ethinyl estradiol and ethynodiol diacetate are excreted in breast milk. M/P ratio not established. Estrogen-progestin combinations may reduce milk production and alter milk composition; use during breastfeeding is generally not recommended. Consider alternative contraception.
Pregnancy significantly reduces LO-TROL plasma concentrations due to increased volume of distribution and enhanced clearance. Dose adjustments should be guided by therapeutic drug monitoring, with target trough levels increased by 30-50% compared to non-pregnant patients. Initiate adjustment in the first trimester and re-evaluate monthly.
Not applicable as use is contraindicated during pregnancy. No pharmacokinetic studies have been conducted to recommend dose adjustments.
Monitor for signs of bronchospasm in patients with asthma or COPD. Use with caution in patients with diabetes as it may mask hypoglycemia symptoms. Taper dose gradually over 1-2 weeks to avoid rebound hypertension.
DEMULEN 1/50-21 is a monophasic oral contraceptive containing ethinyl estradiol 50 mcg and ethynodiol diacetate 1 mg. Use with caution in patients over 35 who smoke due to increased cardiovascular risk. Monitor for breakthrough bleeding, especially in the first three cycles. Consider drug interactions with rifampin, anticonvulsants, and broad-spectrum antibiotics. Administer at the same time daily to maintain efficacy. The 21-day regimen requires a 7-day pill-free interval. Instruct to start on first day of menses or first Sunday after onset.
Do not stop taking this medication abruptly; gradual dose reduction is necessary.,Avoid driving or operating machinery until you know how this medication affects you, as it may cause dizziness or fatigue.,Monitor your blood pressure regularly and report any significant changes.,Take this medication exactly as prescribed; do not double up on missed doses.,Avoid alcohol consumption as it may increase the risk of hypotension.
Take one tablet daily at the same time, starting on the first day of your menstrual period or the first Sunday after your period begins.,Swallow tablet whole with water, with or without food.,After finishing all 21 tablets, wait 7 days before starting a new pack. You will have a withdrawal bleed during this time.,If you miss a tablet by less than 12 hours, take it immediately. If more than 12 hours, take the missed tablet and use backup contraception for 7 days.,Seek emergency medical care for symptoms of blood clots (sudden severe headache, chest pain, shortness of breath, leg pain/swelling), stroke (sudden numbness/weakness, slurred speech), or liver problems (yellowing skin/eyes, dark urine).,Avoid smoking while taking this medication, especially if over age 35, due to increased risk of cardiovascular events.,Inform your healthcare provider about all other medications (including over-the-counter drugs, herbal supplements like St. John's Wort) as they may reduce contraceptive efficacy.,This medication does not protect against HIV or other sexually transmitted infections.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LO-TROL vs DEMULEN 1/50-21, answered by our medical review team.
LO-TROL is a Combination Oral Contraceptive that works by Loteprednol etabonate is a corticosteroid that inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby suppressing inflammation.. DEMULEN 1/50-21 is a Combination Oral Contraceptive that works by DEMULEN 1/50-21 is a combined oral contraceptive containing ethinyl estradiol and ethynodiol diacetate. Ethinyl estradiol and progestins inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation. Progestins also increase cervical mucus viscosity and alter endometrial receptivity, impeding sperm penetration and implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LO-TROL and DEMULEN 1/50-21 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LO-TROL is: IV: 1-2 mg every 2-4 hours as needed; maximum 8 mg/24 hours.. The standard adult dose of DEMULEN 1/50-21 is: 1 tablet (ethinyl estradiol 50 mcg, norethindrone 1 mg) orally once daily for 21 days, followed by 7 days off.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LO-TROL and DEMULEN 1/50-21 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LO-TROL is classified as Category C. LO-TROL is contraindicated in pregnancy. First trimester exposure is associated with a high risk of major congenital malformations, including neural tube defects, cardiovascular an. DEMULEN 1/50-21 is classified as Category C. First trimester: Use contraindicated due to increased risk of congenital anomalies, particularly cardiovascular defects and limb reduction defects, associated with sex hormones. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.